S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.52 (+3.61%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.52 (+3.61%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.52 (+3.61%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.52 (+3.61%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
NASDAQ:DNLI

Denali Therapeutics (DNLI) Stock Price, News & Analysis

$20.66
-0.20 (-0.96%)
(As of 04:25 PM ET)
Today's Range
$20.49
$21.41
50-Day Range
$15.83
$23.35
52-Week Range
$15.45
$33.31
Volume
1.01 million shs
Average Volume
1.22 million shs
Market Capitalization
$2.88 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.67

Denali Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
116.2% Upside
$44.67 Price Target
Short Interest
Bearish
9.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.84
Upright™ Environmental Score
News Sentiment
0.43mentions of Denali Therapeutics in the last 14 days
Based on 58 Articles This Week
Insider Trading
Selling Shares
$1.20 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.86) to ($2.77) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.07 out of 5 stars

Medical Sector

171st out of 948 stocks

Biological Products, Except Diagnostic Industry

22nd out of 157 stocks


DNLI stock logo

About Denali Therapeutics Stock (NASDAQ:DNLI)

Denali Therapeutics Inc., a biopharmaceutical company, developing a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases. It pursues new treatments by assessing genetically validated targets, engineering delivery across the blood-brain barrier, and guiding development through biomarkers that demonstrate target and pathway engagement. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; and DNL343 eIF2B Activator program for amyotrophic lateral sclerosis. The company's other programs comprise SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

DNLI Stock Price History

DNLI Stock News Headlines

Denali Therapeutics (NASDAQ:DNLI) PT Lowered to $95.00
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
4 Analysts Assess Denali Therapeutics: What You Need To Know
Denali spikes after $500M private placement
See More Headlines
Receive DNLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/04/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:DNLI
Fax
N/A
Employees
447
Year Founded
2015

Price Target and Rating

Average Stock Price Target
$44.67
High Stock Price Target
$95.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+116.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-145,220,000.00
Pretax Margin
-43.93%

Debt

Sales & Book Value

Annual Sales
$330.53 million
Book Value
$7.42 per share

Miscellaneous

Free Float
128,166,000
Market Cap
$2.88 billion
Optionable
Optionable
Beta
1.34

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Ryan J. Watts Ph.D. (Age 48)
    Co-Founder, President, CEO & Director
    Comp: $1.04M
  • Dr. Alexander O. Schuth M.D.Dr. Alexander O. Schuth M.D. (Age 51)
    Co-Founder, CFO, COO & Secretary
    Comp: $737.2k
  • Dr. Marc Tessier-Lavigne Ph.D. (Age 64)
    Co-Founder & Independent Director
    Comp: $58.23k
  • Dr. Carole Ho M.D. (Age 51)
    Chief Medical Officer & Head of Development
    Comp: $737.2k
  • Mr. Tyler M. Nielsen (Age 46)
    Senior Vice President of Corporate Finance
  • Dr. Dana Andersen
    Chief Technical and Manufacturing Officer
  • Mr. Joe Lewcock Ph.D.
    Chief Scientific Officer
  • Dr. Laura Hansen
    Vice President of Investor Relations
  • Mr. Chris Walsh
    General Counsel
  • Mr. Mark Rowen
    Vice President of Corporate Development














DNLI Stock Analysis - Frequently Asked Questions

Should I buy or sell Denali Therapeutics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DNLI shares.
View DNLI analyst ratings
or view top-rated stocks.

What is Denali Therapeutics' stock price target for 2024?

8 brokers have issued twelve-month target prices for Denali Therapeutics' shares. Their DNLI share price targets range from $28.00 to $95.00. On average, they anticipate the company's stock price to reach $44.67 in the next twelve months. This suggests a possible upside of 116.2% from the stock's current price.
View analysts price targets for DNLI
or view top-rated stocks among Wall Street analysts.

How have DNLI shares performed in 2024?

Denali Therapeutics' stock was trading at $21.46 at the start of the year. Since then, DNLI shares have decreased by 3.7% and is now trading at $20.66.
View the best growth stocks for 2024 here
.

Are investors shorting Denali Therapeutics?

Denali Therapeutics saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 10,820,000 shares, an increase of 10.0% from the January 31st total of 9,840,000 shares. Based on an average daily volume of 1,140,000 shares, the days-to-cover ratio is presently 9.5 days. Currently, 9.7% of the company's shares are sold short.
View Denali Therapeutics' Short Interest
.

When is Denali Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our DNLI earnings forecast
.

How were Denali Therapeutics' earnings last quarter?

Denali Therapeutics Inc. (NASDAQ:DNLI) announced its quarterly earnings results on Tuesday, February, 27th. The company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.81) by $0.05. Denali Therapeutics had a negative net margin of 36.51% and a negative trailing twelve-month return on equity of 13.50%. During the same quarter last year, the firm earned ($0.75) earnings per share.

What is Ryan Watts' approval rating as Denali Therapeutics' CEO?

1 employees have rated Denali Therapeutics Chief Executive Officer Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among the company's employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Denali Therapeutics own?
When did Denali Therapeutics IPO?

(DNLI) raised $149 million in an initial public offering on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager.

Who are Denali Therapeutics' major shareholders?

Denali Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (10.27%), Vanguard Group Inc. (7.80%), Crestline Management LP (4.08%), Capital Research Global Investors (2.09%), Price T Rowe Associates Inc. MD (1.85%) and Price T Rowe Associates Inc. MD (1.85%). Insiders that own company stock include Alexander O Schuth, Alexander O Schuth, Carole Ho, Marc Tessier-Lavigne, Ryan J Watts, Ryan J Watts, Steve E Krognes, Steve E Krognes, Vicki L Sato and Vicki L Sato.
View institutional ownership trends
.

How do I buy shares of Denali Therapeutics?

Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DNLI) was last updated on 3/4/2024 by MarketBeat.com Staff